Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2018 3
2019 6
2020 8
2021 14
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. Nelde A, et al. Nat Immunol. 2021 Jan;22(1):74-85. doi: 10.1038/s41590-020-00808-x. Epub 2020 Sep 30. Nat Immunol. 2021. PMID: 32999467
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, Reusch J, Jäger S, Denk M, Richter M, Anton L, Weber LM, Roerden M, Bauer J, Rieth J, Wacker M, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Karbach J, Jäger E, Klein R, Rammensee HG, Salih HR, Walz JS. Heitmann JS, et al. Among authors: nelde a. Nature. 2022 Jan;601(7894):617-622. doi: 10.1038/s41586-021-04232-5. Epub 2021 Nov 23. Nature. 2022. PMID: 34814158 Free PMC article. Clinical Trial.
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals.
Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Rachfalski D, Märklin M, Stevanović S, Rammensee HG, Salih HR, Walz JS. Bilich T, et al. Among authors: nelde a. Sci Transl Med. 2021 Apr 21;13(590):eabf7517. doi: 10.1126/scitranslmed.abf7517. Epub 2021 Mar 15. Sci Transl Med. 2021. PMID: 33723016 Free PMC article.
The Peptide Vaccine of the Future.
Nelde A, Rammensee HG, Walz JS. Nelde A, et al. Mol Cell Proteomics. 2021;20:100022. doi: 10.1074/mcp.R120.002309. Epub 2021 Feb 8. Mol Cell Proteomics. 2021. PMID: 33583769 Free PMC article. Review.
NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies.
Wagner TR, Ostertag E, Kaiser PD, Gramlich M, Ruetalo N, Junker D, Haering J, Traenkle B, Becker M, Dulovic A, Schweizer H, Nueske S, Scholz A, Zeck A, Schenke-Layland K, Nelde A, Strengert M, Walz JS, Zocher G, Stehle T, Schindler M, Schneiderhan-Marra N, Rothbauer U. Wagner TR, et al. Among authors: nelde a. EMBO Rep. 2021 May 5;22(5):e52325. doi: 10.15252/embr.202052325. Epub 2021 Apr 27. EMBO Rep. 2021. PMID: 33904225 Free PMC article.
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.
Rammensee HG, Gouttefangeas C, Heidu S, Klein R, Preuß B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bösmüller H, Hoffmann H, Schindler M, Planz O, Wiesmüller KH, Löffler MW. Rammensee HG, et al. Among authors: nelde a. Vaccines (Basel). 2021 Apr 24;9(5):428. doi: 10.3390/vaccines9050428. Vaccines (Basel). 2021. PMID: 33923363 Free PMC article.
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HG, Salih HR, Walz JS. Bilich T, et al. Among authors: nelde a. Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19. Cancer Discov. 2021. PMID: 34011563
36 results